Skip to content

Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization

Status
Withdrawn
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01305681
Enrollment
0
Registered
2011-03-01
Start date
2011-05-06
Completion date
2012-02-21
Last updated
2019-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurogenic Bladder, Urinary Retention

Brief summary

The primary objective of our study is to examine characteristics of bacteria that are discovered in urine from pediatric patients that utilize either LoFric® or non-LoFric® catheters for self intermittent catheterization. The investigators hypothesize that the hydrophilic nature of the LoFric® catheter will alter the microbial environment and reduce clinically significant urinary tract infections in patients with neurogenic bladder compared to a similar population using standard catheters. Secondary outcomes will be comparing the incidence of clinical urinary tract infections between patients that use standard catheters and those that use LoFric catheters. Lastly, patient satisfaction using LoFric catheters compared to standard catheters will be assessed.

Detailed description

The investigators will randomize patients with neurogenic bladder into 2 groups after the have been matched for age, gender and mobility. The first group will continue with their current intermittent catheterization system (a non-LoFric® catheter) while the second group will receive sufficient LoFric® catheters to complete the study. The investigators will collect the urine at the start of the study, and then at 3, 6, 12, and 18 months and sent for culture. If a child develops a urinary tract infection, the investigators will have the patient collect the urine and the urine will be cultured and the organism will be identified. Using an existing bladder cell line, the investigators will inoculate the bladder cells with any bacteria that grows from any sample and then determine the interleukin-6 response of the bladder cell line following inoculation with the bacteria. This will determine if the initiate a high or low cytokine response which the investigators have correlated to clinical risk of symptomatic urinary tract infection The investigators will provide a patient satisfaction survey at the start of the study, prior to randomization and at the completion of the study to determine satisfaction with LoFric® catheters.

Interventions

DEVICELoFric® catheters during clean intermittent catheterization

LoFric® catheters during clean intermittent catheterization

Sponsors

Dentsply Sirona Implants and Consumables
CollaboratorINDUSTRY
Nationwide Children's Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Please close this study at ct.gov as we have not further data at NCH as Dr. Vanderbrink left NCH in 2011.

Intervention model description

It appears Dr. Vanderbrink left Nationwide Children's Hospital in 2011 and efforts to reach Dr. Vanderbrink have been unsuccessful. The study expired with the NCH IRB before it was ever approved for a 2nd year.

Eligibility

Sex/Gender
ALL
Age
No minimum to 35 Years
Healthy volunteers
No

Inclusion criteria

* Patients who perform clean intermittent catheterization on a regular basis

Exclusion criteria

* Patients on daily continuous antibiotic therapy

Design outcomes

Primary

MeasureTime frame
Characteristics of bacteria discovered in urine of pediatric patients using LoFric® catheters during clean intermittent catheterization18 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026